NeuroMetrix, Inc. (Nasdaq: NURO), www.neurometrix.com,
a medical device company focused on the diagnosis and treatment of the
neurological complications of diabetes, today announced that Shai N.
Gozani M.D., Ph.D., President and Chief Executive Officer, is scheduled
to speak at the 6th Annual OneMedForum at the Sir Frances
Drake Hotel, San Francisco, CA on January 7-9, 2013. Dr. Gozani intends
to provide an update on the Company’s business activities and on its
diabetes products including NC-stat® DPNCheck™,
a diagnostic test for systemic neuropathies such as diabetic peripheral
neuropathy (DPN), and the SENSUS™ pain management device for relief of
chronic intractable pain.
NeuroMetrix's presentation is scheduled for Tuesday, January 8, 2013 at
11:40 am (Pacific Standard Time), 2:40 pm (Eastern Standard Time). A
live audio webcast will be available on the investor relations section
of the corporate website - www.neurometrix.com.
This webcast will be archived after the live event.
About NeuroMetrix
NeuroMetrix is an innovative medical device company that develops and
markets home use and point-of-care devices, associated consumables, and
support software for the treatment and management of diabetes and its
complications. The company is focused on nerve related complications of
diabetes, called diabetic neuropathies, which affect over 50% of people
with diabetes. If left untreated, diabetic neuropathies trigger foot
ulcers that may require amputation, cause disabling chronic pain, and
increase the risk of falling in the elderly. The annual cost of diabetic
neuropathies has been estimated at $14 billion in the United States. The
company’s products are used by physicians and other clinicians in retail
health settings such as pharmacies, and by managed care organizations to
optimize patient care and reduce healthcare costs. The company markets
the NC-stat DPNCheck device, which is a rapid, accurate, and
quantitative point-of-care test for diabetic neuropathy. This product is
used to detect diabetic neuropathy at an early stage and to guide
treatment. The company has also begun to market the SENSUS Pain
Management System for treating chronic pain, focusing on physicians
managing patients with painful diabetic neuropathy. The company has
additional therapeutic products in its pipeline. For more information,
please visit http://www.neurometrix.com.
